Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$7.26
+0.8%
$9.31
$2.09
$14.84
$514.66M0.055.32 million shs2.25 million shs
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$9.09
$9.06
$4.01
$9.10
$1.20B0.834.50 million shsN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$1.32
$1.01
$0.41
$1.75
$242.38M0.92.13 million shs559,088 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$14.71
-0.9%
$15.77
$4.60
$20.90
$644.00M0.74399,172 shs189,746 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+1.69%+4.50%-16.76%-22.83%+37.93%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00%0.00%0.00%0.00%+84.01%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-4.35%0.00%+46.67%+159.33%+64.88%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-2.94%-1.07%-5.48%+31.68%+160.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
1.358 of 5 stars
3.31.00.00.03.11.70.0
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
3.7329 of 5 stars
3.03.00.04.21.02.50.6
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
1.4165 of 5 stars
2.21.00.00.03.14.20.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.67
Moderate Buy$15.00106.61% Upside
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
2.00
HoldN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.00
Hold$3.50165.15% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.33
Hold$16.5712.65% Upside

Current Analyst Ratings

Latest YMAB, ALT, NKTR, and CTIC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
3/28/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/6/2024
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$0.50 ➝ $1.00
3/6/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
3/5/2024
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/4/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $26.00
3/4/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $26.00
2/20/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $21.00
2/13/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
2/12/2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$12.00 ➝ $18.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$430K1,196.89N/AN/A$2.75 per share2.64
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$53M22.62N/AN/A($0.14) per share-64.93
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$90.12M2.69N/AN/A$0.69 per share1.91
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$84.82M7.59N/AN/A$2.32 per share6.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$276.06M-$1.46N/AN/AN/A-306.31%-96.80%-37.17%5/14/2024 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%5/13/2024 (Estimated)

Latest YMAB, ALT, NKTR, and CTIC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.33+$0.02-$0.12N/A$0.04 million
3/4/202412/31/2023
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$0.21-$0.22-$0.01-$0.22$17.09 million$23.89 million    
2/29/2024Q4 2023
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
17.26
17.26
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/A
1.27
1.26
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
6.45
6.14
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
5.52
5.27

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
91.45%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
7.61%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
3.07%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
21.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5970.89 million67.99 millionOptionable
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
127131.88 million121.84 millionOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
137183.62 million177.98 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
10043.78 million34.37 millionOptionable

YMAB, ALT, NKTR, and CTIC Headlines

SourceHeadline
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
globenewswire.com - April 26 at 7:05 AM
Y-mAbs to Present at 2024 ASCO Annual MeetingY-mAbs to Present at 2024 ASCO Annual Meeting
globenewswire.com - April 25 at 4:05 PM
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7%Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7%
marketbeat.com - April 23 at 4:47 PM
New Strong Buy Stocks for April 19thNew Strong Buy Stocks for April 19th
zacks.com - April 19 at 7:50 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%
finance.yahoo.com - April 18 at 1:21 PM
New Strong Buy Stocks for April 17thNew Strong Buy Stocks for April 17th
zacks.com - April 17 at 8:30 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%
marketbeat.com - April 11 at 11:58 AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by AnalystsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analysts
marketbeat.com - April 10 at 2:30 AM
Y-mAbs Therapeutics (NASDAQ:YMAB)  Shares Down 3.3% Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3%
marketbeat.com - April 9 at 11:46 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%
marketbeat.com - April 3 at 3:27 PM
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19
marketbeat.com - April 2 at 11:19 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%
marketbeat.com - April 1 at 2:01 PM
Denali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Denali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
marketbeat.com - April 1 at 6:12 AM
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a BetWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
zacks.com - March 28 at 10:56 AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%
marketbeat.com - March 26 at 12:38 PM
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
zacks.com - March 20 at 8:40 AM
Y-mAbs Therapeutics Finance Chief Bo Kruse ResignsY-mAbs Therapeutics Finance Chief Bo Kruse Resigns
marketwatch.com - March 15 at 8:31 AM
Y-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
finanznachrichten.de - March 14 at 2:58 PM
Y-mAbs Therapeutics CFO Bo Kruse To RetireY-mAbs Therapeutics CFO Bo Kruse To Retire
markets.businessinsider.com - March 14 at 9:57 AM
Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerY-mAbs Therapeutics Announces Resignation of Chief Financial Officer
globenewswire.com - March 14 at 9:05 AM
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
zacks.com - March 12 at 10:55 AM
BAMF, Corewell Health partner on clinical trial for advanced cancer treatmentBAMF, Corewell Health partner on clinical trial for advanced cancer treatment
crainsgrandrapids.com - March 11 at 3:17 PM
Cracking The Code: Understanding Analyst Reviews For Y-mAbs TherapeuticsCracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
markets.businessinsider.com - March 6 at 6:21 PM
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great ChoiceAre You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
zacks.com - March 5 at 1:01 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
CTI BioPharma logo

CTI BioPharma

NASDAQ:CTIC
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Nektar Therapeutics logo

Nektar Therapeutics

NASDAQ:NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Y-mAbs Therapeutics logo

Y-mAbs Therapeutics

NASDAQ:YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.